Gli is a hypoglycemic agent that can inhibit NLRP3 mediated production of IL-1β by blocking P2X7 ion-channels; this compound also modulates TRPM4, a cation channel that mediates axonal and neuronal degeneration in Multiple Sclerosis (MS) [45]. Here, IL1B is linked to myeloid sarcoma.